Trial Profile
A Single-Arm, Multicenter, Phase 1b Study With an Expansion Cohort to Evaluate Safety and Efficacy of Necitumumab in Combination With Abemaciclib in Treatment of Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Necitumumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly and Company (India) Pvt. Ltd
- 02 Jul 2019 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Planned End Date changed from 12 Nov 2018 to 12 May 2019.
- 15 Mar 2018 This trial has been completed in Spain